Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine-Reference-Cited by-同舟云学术

Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine

Published:2015-10-15 Issue:38 Volume:6 Page:40642-40654
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Subbiah Vivek¹,Wagner Michael J.¹,McGuire Mary F.²,Sarwari Nawid M.³,Devarajan Eswaran⁴,Lewis Valerae O.⁴,Westin Shanon⁵,Kato Shumei¹,Brown Robert E.²,Anderson Pete⁶

Affiliation:

1. Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

2. Department of Pathology & Laboratory Medicine, The University of Texas-Houston Medical School, Houston, TX 77030, USA

3. Department of Internal Medicine, The University of Texas-Houston Medical School, Houston, TX 77030, USA

4. Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

5. Division of Gynecological Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

6. Department of of Pediatric Hematology/Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland;Oncology Research and Treatment;2024-05-07

2. Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma;Oncoscience;2023-09-20

3. Beneath the Layers: Deciphering the Molecular Pathways, Therapeutic Avenues, and Neurological Connections of Soft Tissue Sarcomas;Cureus;2023-09-04

4. Proteomics: A groundbreaking development in cancer biology;Proteomics;2023

5. Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming;Cancers;2022-09-02